降糖药对循环PCSK9水平影响的研究进展  

Research progress of hypoglycemic agents on circulating PCSK9 concentration

作　　者：范伟杰 李上海 黄瑞娜 张心斌 吴万泰 梁伟钧 Fan Weijie;Li Shanghai;Huang Ruina;Zhang Xinbin;Wu Wantai;Liang Weijun(Department of Cardiology,Guangdong Medical University Affiliated Hospital,Zhanjiang 524000,China)

机构地区：[1]广东医科大学附属医院心内科,湛江524000

出　　处：《中国综合临床》2025年第1期71-75,共5页Clinical Medicine of China

基　　金：湛江市科技计划项目(2022A01187)。

摘　　要：糖尿病患者长期糖代谢紊乱常伴有血脂异常,尤其低密度脂蛋白胆固醇(low-density lipoprotein cholesterol,LDL-C)水平的升高,是动脉粥样硬化性心血管疾病(atherosclerotic cardiovascular disease,ASCVD)发展的重要危险因素。最近国内外研究还发现糖尿病会导致前蛋白转化酶枯草溶菌素9(proprotein convertase subtilisin/kexin type 9,PCSK9)水平升高。鉴于PCSK9过度表达对LDL-C水平及心血管风险、动脉粥样硬化均有深远影响,故探究降糖药物在治疗糖尿病时能否降低PCSK9的水平具有重要意义。我们总结了各类降糖药物对循环PCSK9水平影响的研究结果,以期为糖尿病的优化治疗提供思路。Long-term glucose metabolism disorders in patient with diabetes is often accompanied by dyslipidemia,especially the elevated level of low-density lipoprotein cholesterol(LDL-C).It is an important risk factor for the development of atherosclerotic cardiovascular disease(ASCVD).Recent studies at home and abroad have also found that diabetes can lead to increased levels of proprotein convertase subtilisin/kexintype 9(PCSK9).In view of the profound influence of PCSK9 overexpression on low density lipoprotein cholesterol level,cardiovascular risk and atherosclerosis,it is of great significance to explore whether hypoglycemic drugs can reduce the level of PCSK9 in the treatment of diabetes.We summarized the results of the study on the effects of various hypoglycemic drugs on circulating PCSK9 concentration in order to provide ideas for the optimal treatment of diabetes.

关 键 词：前蛋白转化酶枯草溶菌素9 糖尿病 降糖类药物 低密度脂蛋白胆固醇 

分 类 号：R54[医药卫生—心血管疾病]